Treatment of Tuberculosis in Adult and Adolescent Patients Co-infected with the Human Immunodeficiency Virus (HIV)

This pocket-size drug treatment card for clinicians provides information on therapy options and recommendations for the co-infected patient including drug interactions and side effects.

NOTE:

The following resources were used in developing this card and should be consulted for more complete and/or up-to-date information:

Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents MMWR 2004; 53 (RR15)

Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors MMWR 2000; 49 (No. 9)

Prevention and Treatment of Tuberculosis among Patients Infected with Human Immunodeficiency Virus: Principles of Therapy and Revised Recommendations MMWR 1998; 47 (No. RR-20)

Treatment of Tuberculosis MMWR 2003; 52 (No. RR-11)

DHHS Panel on Antiretroviral Therapy Guidelines for Adults and Adolescents – Notice on Nelfinavir FDAPfizer Letter, September 13, 2007

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council, October 10, 2006

American Academy of Pediatrics, Committee on Infectious Diseases. Tuberculosis. In L.K. Pickering (Ed.), 2006 Red Book: Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2006: 678-704.

AIDSInfo website - U.S. Department of Health and Human Services (DHHS)